Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells

Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells

Background: Multiple myeloma (MM) is the second most common hematological cancer after lymphoma. It is characterized by the accumulation of clonal malignant plasma cells within the bone marrow. The development of drug resistance remains a major problem for effective treatment of MM. Understand the m...

Full description

Bibliographic Details
Main Authors: Claire Gourzones, Céline Bellanger, Sylvain Lamure, Ouissem Karmous Gadacha, Elvira Garcia De Paco, Laure Vincent, Guillaume Cartron, Bernard Klein, Jérôme Moreaux
Format: Article
Language:English
Published: MDPI AG 2019-03-01
Series:Cancers
Subjects:
GSH
multiple myeloma
reactive oxygen species
melphalan
drug resistance
NRF2
Online Access:https://www.mdpi.com/2072-6694/11/4/439

Internet

https://www.mdpi.com/2072-6694/11/4/439

Similar Items